Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid
Status:
Not yet recruiting
Trial end date:
2023-11-25
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of rituximab combined with omalizumab in achieving sustained
complete remission, evaluated by Bullous Pemphigoid Disease Area Index (BPDAI) in patients
with bullous pemphigoid (BP) at Week 24 in patients with active moderate-to-severe BP
refractory to rituximab therapy alone.